Drug Profile
Ivermectin extended release - Lyndra
Alternative Names: LYN-063; LYN-163Latest Information Update: 24 Jun 2022
Price :
$50
*
At a glance
- Originator Lyndra
- Class Antimalarials; Antineoplastics; Antiparasitics; Antivirals; Macrolides; Skin disorder therapies; Small molecules
- Mechanism of Action Chloride channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Malaria
Most Recent Events
- 09 Jun 2022 Phase-I clinical trials in Malaria (In volunteers, In adults) in Australia, USA (PO) (9360477; 700342576)
- 22 Oct 2021 Ivermectin extended release is still in preclinical trials for Malaria in USA
- 10 Sep 2021 Lyndra plans a phase I trial for Malaria (In volunteers, In adults) in Australia (PO, Controlled release) (ACTRN12621001218886)